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Improving Smoking Cessation Outcomes Through 
Tailored-Risk Patient Messages at a University Hospital 
Tobacco Cessation Service 
David Gonzales, PhD; Wendy G. Bjornson, MPH; Catherine J. Markin, MD; Trisha M. Coleman, MA; 
Frances Favela, MPH; Noal Clemons, BA; Caroline Koudelka, MPH; Jodi A. Lapidus, PhD 
Background: Postdischarge follow-up is a critical step for increasing effectiveness of hospital smoking cessation treatment. 
A quality improvement project was undertaken at an academic medical center tobacco cessation consult service to evaluate 
whether a tailored message (TM) linking immediate risks of continued smoking—particularly carbon monoxide exposure—
to hospital recovery would stimulate more patient interest in the hospital’s cessation treatment, including agreement to 
postdischarge follow-up, compared to patients receiving the usual treatment protocol with a standard message (SM) regarding 
more general health benefits of abstinence. 
Methods: Data from 697 smokers ordered/referred for smoking cessation treatment in 2013 who received either the SM 
(January–April; n = 323) or the TM (April–November; n = 374) were analyzed. 
Results: Multivariate regression analysis showed that the TM was associated with significantly greater agreement for follow- 
up (odds ratio [OR] = 10.83, 95% confidence interval [CI] = 3.66–32.04, p < 0.0001) than the SM. Those patients who 
received the TM were more willing to try to remain abstinent postdischarge (willingness score = 10, p = 0.0052) and engaged 
in longer consults (consult time > 10 minutes, p = 0.0075) than SM patients. TM patients also self-reported a higher 
continuous abstinence rate (OR = 2.07, 95% CI = 1.17–3.66, p = 0.0130] at follow-up than SM. 
Conclusion: Linking risks of continued smoking, particularly carbon monoxide exposure, to hospital patients’ immediate 
recovery following discharge in a treatment protocol resulted in longer consult times and increased agreement to follow-up 
compared to the usual protocol message. The TM was integrated into the hospital tobacco cessation intervention as standard 
of care. 
Nearly 38 million Americans continue to smoke 1 and some are admitted to smoke-free hospitals every year 
due to smoking-related disease. Unfortunately, many re- 
sume smoking after discharge, risking their recovery and 
readmission. 2 Continued smoking increases risks for infec- 
tion, 3 fracture union failures, 4 cardiovascular events and 
death for those with cardiovascular disease, 5–7 suppressed 
immune response, 3 connective tissue graft failure, 8 de- 
creased effectiveness of cancer treatments, 9 and reduced sur- 
vival time for cancer patients, 10 as well as other risks. 2 
It is estimated that direct health care costs for smoking- 
related illnesses exceed $170 billion annually. 11 The exces- 
sive human and financial cost of smoking, particularly for 
health care, has spurred decades of research into how to in- 
tervene with patients as they come through the health care 
system. Multiple guidelines and recommendations have 
been developed, and tobacco treatment for hospital patients 
has been incorporated into Joint Commission quality mea- 
sures. 12 , 13 
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The tobacco treatment model for hospitals has been 
adapted from national clinic-based treatment guidelines 
and clinical trial data. Recommended intervention includes 
asking each patient about smoking, advising specifically 
about the importance of quitting, assessing willingness to 
quit, developing a treatment plan including medications, 
and, of high importance, providing follow-up after dis- 
charge. 2 These components, applied in a variety of hospi- 
tal randomized controlled trials (RCTs), have been shown 
to be efficacious for patients eligible and willing to partic- 
ipate. 14–20 Postdischarge follow-up has been shown to be 
key to the effectiveness of hospital smoking cessation inter- 
ventions. 2 , 16 , 17 Although RCT data provide good evidence 
for the efficacy of the recommended treatments, study in- 
clusion/exclusion criteria limited participation, 18–21 which 
may limit generalizability of findings. 22 More restrictive 
RCT inclusion/exclusion criteria help explain why some 
hospital-based RCTs report less than 30% of patients with 
a current smoking history eligible for study entry. 18–21 
There is a modest but growing literature on methods 
and outcomes for non-RCT hospital-supported cessation 
services that aim to reach all smoking patients. 23–26 How- 
ever, even with fewer restrictions and greater opportunity 
to increase reach, patient lack of interest or willingness to 
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participate in treatment remain obstacles. As we discov- 
ered in our program, an important reason for lack of inter- 
est was that patients were understandably more concerned 
about their immediate illness/condition and recovery than 
in quitting tobacco use. We also learned from the tobacco 
treatment specialists ( T TSs) and from the provider advisory 
board that our medical staff was not regularly informing pa- 
tients about the link between their continued smoking and 
the risk it posed to their recovery. In fact, we also learned 
that there were gaps in the understanding of the medical 
teams about the nature of these links themselves. Consid- 
ering this, we wondered if we could adapt our protocol to 
make it more relevant and compelling for patients by in- 
forming them about the link between continued smoking 
and recovery. 
In particular, we wondered if patients would benefit 
from more specific information about carbon monoxide 
(CO). Because the lay public already had some familiar- 
ity with the risks of CO and the importance of having CO 
monitors in their homes, 27 we thought that providing novel 
information about the link between CO from their smok- 
ing and the risks to their recovery might engage more pa- 
tients to participate in treatment and follow-up. Specifically, 
we wanted to help explain how CO, with its higher affin- 
ity for hemoglobin than oxygen, reduces blood oxygena- 
tion 5 , 7 , 28 resulting in increased risks of complications for 
wound recovery 29 , 30 increased cardiac stress, 5–7 , 28 and sup- 
pressed immune response. 3 
To explore these questions, we developed a quality im- 
provement (QI) project aimed at modifying our standard 
approach used with patients referred for cessation services 
to include more tailored information about the risks of con- 
tinued smoking to their recovery. The messages, methods, 
and outcomes are the subjects of this article. 
METHODS 
Setting 
Patients were admitted to a regional academic medical cen- 
ter in Portland, Oregon. Inpatient tobacco dependence 
treatment was provided by a Tobacco Cessation Consult 
Service (Consult Service) and managed by our Smoking 
Cessation Center in the Division of Pulmonary and Crit- 
ical Care Medicine from 2007 to 2014. 
Procedures 
Orders/referrals were sent via the electronic health record 
(EHR) system. A current history of tobacco use was the only 
criterion required for medical teams to order/refer patients 
for tobacco dependence treatment. Master’s level trained 
TTSs reviewed patient medical records prior to going to 
the floors to engage patients in participating in the inter- 
vention. 
Tobacco Cessation Consult Protocol 
The Consult Service Protocols, initially developed in 2007–
2008, were established before the more recent Joint Com- 
mission guidelines 13 but were consistent with the 2008 up- 
date to Treating Tobacco Use and Dependence , the US Pub- 
lic Health Service Clinical Practice Guideline. 2 Our stan- 
dard treatment protocol included an introduction of the 
TTS, an engagement message about how stopping smok- 
ing was important to long-term health, and an assessment 
of current withdrawal symptoms. From there, patients were 
asked about their history of tobacco use/abstinence, their 
willingness to try to remain abstinent postdischarge (0–10 
scale; 10 = highest level of willingness), their confidence in 
remaining abstinent postdischarge (0–10 scale), and their 
current stress level (0–10 scale). They were also asked if 
there were other smokers in the household, if smoking was 
allowed inside the home, if they had support from others 
for quitting, and if anyone else at the hospital had talked 
with them about tobacco use. The TTS then answered any 
questions and provided education regarding other risks of 
tobacco smoke exposure such as increased clearance rates of 
psychotropic 31 or anti-cancer drugs, 9 as appropriate; educa- 
tion regarding general health benefits of tobacco abstinence; 
behavioral counseling to support abstinence; and recom- 
mendation/referral to the tobacco quitline. 
Discharge planning included recommendations/orders 
for cessation medications and a TTS staff request for ver- 
bal permission from the patient to allow a phone follow-up 
visit two to three weeks postdischarge. For patients unavail- 
able or unable to engage with the TTS, at least two more 
attempts were made. For those who opted out, written ces- 
sation information, including the quitline number, was left 
in the room. Information was documented on the Con- 
sult Treatment Form and entered into the Administrative 
Database. For patients agreeing to a follow-up phone visit, 
three contact attempts were made beginning two weeks 
after discharge. The TTS recorded patient self-reported 
smoking status since discharge (continuously abstinent or 
relapsed to less than, equal to, or greater than before hos- 
pitalization), use of cessation medications, use of quitline 
services, follow-up with primary care provider, and follow- 
up with the patient’s health plan. The TTS then provided 
behavioral support to encourage remaining/achieving absti- 
nence, entered notes into the EHR, and updated the med- 
ical team with the status of the patient’s order/referral. 
Protocol Changes 
Original Approach: Standard Message (SM) 
Script. In the original approach the TTS delivered the fol- 
lowing standard engagement message: 
I’m ( staff name ) from the Pulmonary Division. We try to talk to 
everyone who has used tobacco recently, because quitting smoking 
is one of the best things that you can do for your health. I also 
want to check on your comfort. Are you having any craving or 
withdrawal symptoms now? 
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Education was then provided regarding benefits of re- 
maining abstinent from tobacco on overall health based on 
patient interest. 
Revised Approach: Tailored Message (TM) Script. 
In the revised approach the TTS delivered the following 
tailored engagement message: 
I’m ( staff name ) from the Pulmonary Division. We try to talk with 
everyone who has smoked in the past year because we are con- 
cerned about the effects of carbon monoxide from smoke expo- 
sure on your recovery from your ( admitting diagnosis ). CO re- 
duces oxygen in your blood and can affect your recovery. We also 
want you to be as comfortable as possible while you are at OHSU. 
Are you having any cravings or withdrawal symptoms now? 
This was followed with education regarding CO risks. 
The following is a lay language example of CO risk educa- 
tion: 
If you are exposed to tobacco smoke after you leave the hospi- 
tal, the carbon monoxide in smoke will reduce the amount of 
oxygen in your blood, because it will attach to your red blood 
cells before oxygen. This can cause serious problems for your 
( surgery, wound, infection, etc .) recovery, since reduced oxygen 
impacts healing. You need good oxygen levels to heal and recover. 
Carbon monoxide also causes your heart to have to work harder 
and to pump blood faster to try to bring more oxygen to the rest 
of your body. We don’t want you to put extra stress on your heart. 
We advise all our patients to stay off cigarettes and to stay away 
from other people’s smoke when they go home. We don’t want 
anything to happen to you after you leave the hospital. 
CO risk education was provided prior to assessing pa- 
tient willingness to remain abstinent postdischarge. Addi- 
tional education was provided on risks of CO, based on 
patient interest. Patients in both groups received education 
on the general health benefits of abstinence. 
Research Questions 
Primary Question. Will a tailored message (TM) that 
links risks of continued smoking, including carbon monox- 
ide (CO) exposure, to postdischarge recovery increase pa- 
tient agreement to follow-up compared to patients who 
receive only our standard message (SM) that educates on 
more general health benefits of smoking abstinence? 
Secondary Questions. (1) Are there differences in self- 
reported continuous abstinence rates at postdischarge for 
TM patients completing follow-up compared to those who 
receive the SM? (2) What variables predict any differences 
in outcomes between groups? (3) Assuming differences in 
outcomes between TM and SM message groups, can meth- 
ods by which these differences occur be demonstrated? 
Study Design 
To test the effect of the revised approach with the TM com- 
pared to the original approach with our SM, we designed 
an evaluation using two sequential groups during the rou- 
tine delivery of tobacco cessation consultations for which 
we had orders/referrals in 2013. Sample size was calculated 
to guide timing for each group’s data collection. Data for 
the SM group were collected first and analyzed for patients 
discharged between January 25 and April 25. When the 
sample size for SM was reached, the TTSs were trained to 
deliver the TM. Data from the TM group were collected 
second and analyzed for patients discharged between April 
29 and November 30. Data for each consultation were en- 
tered into our Administrative Database and identified by 
message group. 
Database 
All data were anonymized. Data from the Consult Service 
database were combined with Institutional Review Board–
approved data from our Research Data Warehouse (RDW). 
Patient variables from the RDW were age, sex, type of ad- 
mission (emergent, trauma, urgent medical, elective med- 
ical, urgent surgical, elective surgical), insurance coverage 
(or no coverage), history of mental disorders (including ad- 
dictions), length of stay, cessation medication orders while 
hospitalized, and discharge diagnoses (International Classi- 
fication of Diseases, Ninth Revision, Clinical Modification 
[ICD-9-CM] codes). 
Patient variables from the Consult Service database in- 
cluded: smoking during hospitalization, cravings during 
hospitalization, having a first cigarette less than 30 minutes 
after waking, recently having cut down on smoking, liv- 
ing with other smokers, smoking inside the home, average 
number of cigarettes smoked per day in the past 30 days, av- 
erage number of cigarettes smoked per day in the past year, 
self-reported stress level, and having other hospital staff ask 
about tobacco use. 
These variables were selected because most are associated 
with cessation outcomes reported in the literature (such 
as age, being male, income 32 ; nicotine dependence vari- 
ables such as cigarettes per day, 2 , 33 time to first cigarette, 
stress level, having others support cessation, and confidence 
in quitting 2 ; history of mental health disorder [including 
substance abuse] 2 , 32 , 33 ; history of prior quit attempts and 
willingness to try to quit smoking 32 ; and no other smok- 
ers in the household 2 , 32 , 33 ) or are specific to hospital pop- 
ulations (such as no withdrawal symptoms after admis- 
sion, no smoking while in the hospital, length of hospi- 
tal stay 23 ; use of cessation medications in the hospital 34 ; 
type of admission 26 ; and specifically an admission for car- 
diac disease 16 ). Data on three additional variables collected 
during patient consultations were also selected as measures 
of interest and willingness in intervention participation: 
the amount of time spent with the patient during consult 
(consult time), 23 patient-reported willingness to remain ab- 
stinent (willingness score), 2 and confidence in remaining 
abstinent after discharge (confidence score). Data on two 
variables collected during postdischarge follow-up calls 
were also selected: self-reported smoking status and the use 
of stop-smoking medications. 
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Table 1a. Demographic Variable Comparisons ∗ for Patients with Completed Consults in Standard Message (SM) 
Group vs. Patients with Completed Consults in Tailored Message (TM) Group 
SM Group: N = 232 
(Jan 25–Apr 25, 2013) 
TM Group: N = 298 
Apr 29–Nov 30, 2013) p Value 
Continuous Variables Mean (SD) Mean (SD) t -test 
Average age (at admission) 50.6 (14.9) 51.9 (13.7) 0.3096 
Average length of stay 7.5 (7.7) 6.8 (5.8) 0.2276 
Categorical Variables n (%) n (%) chi-square † 
Gender 
Male 131 (56.5) 182 (61.1) 0.2845 
Female 101 (43.5) 116 (38.9) 
Insurance class 
Commercial + Contracts 58 (25.0) 65 (21.8) 0.3884 
Medicaid 68 (29.3) 77 (25.8) 0.3738 
Medicare 56 (24.1) 95 (31.9) 0.0501 
Nonsponsored 32 (13.8) 43 (14.4) 0.8348 
Other/unknown sponsored 18 (7.8) 18 (6.0) 0.4354 
Admission type 
Emergent 75 (32.3) 101 (33.9) 0.7043 
Trauma 15 (6.5) 13 (4.4) 0.2829 
Urgent medical 61 (26.3) 89 (29.9) 0.3650 
Elective medical 14 (6.0) 19 (6.4) 0.8718 
Urgent surgical 11 (4.7) 10 (3.4) 0.4172 
Elective surgical 56 (24.1) 66 (22.1) 0.5892 
History psych/drug/alcohol 
Yes 191 (82.3) 254 (85.2) 0.3655 
Cessation Medication Orders 
At discharge Yes 80 (34.5) 113 (37.9) 0.4147 
In-hospital Yes 150 (64.7) 223 (74.8) 0.0109 
Primary discharge diagnosis 
Cancer 31 (13.4) 41 (13.8) 0.8949 
Endocrine 5 (2.2) 6 (2.0) 0.9096 
Cardiovascular 46 (19.8) 78 (26.2) 0.0868 
Mental and behavioral 6 (2.6) 5 (1.7) 0.4668 
Pulmonary 16 (6.9) 13 (4.4) 0.2031 
Gastrointestinal 18 (7.8) 23 (7.7) 0.9862 
Genitourinary 3 (1.3) 3 (1.0) 0.7572 
Orthopedics 22 (9.5) 18 (6.0) 0.1366 
Injury 40 (17.2) 55 (18.5) 0.7175 
Other /Missing 45 (19.4) 56 (18.8) 0.8604 
∗ Variables derived from electronic medical record data stored and requested from the Research Data Warehouse. 
† p values reported for nonbinary categorical variables test specified level against all other levels combined. 
SD, standard deviation; history psych/drug/alcohol, patient history of psychological diagnosis or drug or alcohol abuse. 
Statistical Methods 
Analyses were performed using SAS 9.4 (SAS Institute Inc., 
Cary, North Carolina). Significance tests for comparisons 
of variables among SM vs. TM patients reported on Tables 
1a and b were performed by Student’s t -test for continuous 
variables and chi-square test for categorical variables. 
Logistic Regression. Initially, associations between 
message group (TM vs. SM) and outcomes for agreement to 
follow-up and for abstinence at follow-up were determined 
using univariate logistic regression models. Following this 
step, bivariate models were built using message group and 
one of several potentially confounding covariates to predict 
each outcome. Results of these bivariate models were used 
in the development of two multivariate regression models. 
The augmented backward elimination (ABE) tech- 
nique 35 was used to build the multivariate models to predict 
the effect of group on patient agreement to follow-up and 
self-reported abstinence at follow-up. The ABE technique 
was selected because it assesses the confounding effects of 
each covariate and excludes variables deemed insignificant 
in the final model. The resulting model is thereby simpli- 
fied and observations can be included that may have had 
missing values for the omitted variables. 35 Criteria for in- 
clusion/exclusion from the models were as follows: 
1. Bivariate p value < 0.2500 for inclusion of covariate 
into initial multivariate model 
2. P value > 0.1000 and change-in-estimate of < 20% 
to remove covariates (one by one) from multivariate 
model 
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Table 1b. Consult Assessment Variable ∗ Comparisons for Patients with Completed Consults in Standard Message 
(SM) Group vs. Patients with Completed Consults in Tailored Message (TM) Group 
SM Group † : (Jan 
25–Apr 25, 2013) 
TM Group † : (Apr 
29–Nov 30, 2013) p Value 
Continuous Variables Mean (SD) Mean (SD) t -test 
Average # cigarettes in last 30 days 14.0 (9.8) 14.7 (9.6) 0.4204 
Average # cigarettes in last year 17.1 (11.2) 17.5 (10.6) 0.6475 
Categorical Variables n (%) n (%) chi-square ‡ 
Cravings during hospitalization 
Yes 101 (44.1) 174 (58.8) 0.0008 
Smoking during hospitalization 
Yes 30 (13.1) 16 (5.4) 0.0018 
First cigarette < 30 min after waking 
Yes 161 (70.3) 255 (85.9) < 0.0001 
Recently cut down on smoking 
Yes 68 (29.8) 66 (22.2) 0.0452 
Live with other smokers 
Yes 124 (53.7) 135 (45.3) 0.0559 
Smoke inside the home 
Yes 76 (33.5) 97 (32.6) 0.8223 
Other hospital staff discussed tobacco use 
Yes 86 (40.0) 73 (24.8) 0.0002 
Stress level 
Low 60 (28.4) 100 (34.0) 0.1839 
Mod 70 (33.2) 101 (34.4) 0.7826 
High 81 (38.4) 93 (31.6) 0.1151 
Cessation medication use at follow-up 
Yes 48 (36.6) 55 (31.1) 0.3059 
Consult Mediators n (%) n (%) chi-square 
Willingness score of 10 
Yes 102 (44.0) 142 (47.7) 0.3984 
Confidence score of 10 
Yes 42 (18.1) 33 (11.1) 0.0213 
10 or more minutes spent in consult 
Yes 83 (35.8) 206 (69.1) < 0.0001 
∗ Variables derived from Smoking Cessation Administrative Database. 
† Sample sizes vary slightly due to missing values. 
‡ P values reported for nonbinary categorical variables test specified level against all other levels combined. 
SD, standard deviation; willingness score, willingness to remain abstinent from smoking postdischarge; confidence score, confidence in 
remaining abstinent from smoking postdischarge. 
3. Assessment of final model with each covariate not in- 
cluded in the first multivariate model; exclusion of 
variable if p value > 0.1000 and change-in-estimate 
< 20% 
The three mediating measures of intervention interest 
and willingness were not included in the first multivariate 
model built to predict agreement to follow-up. A second 
multivariate model was developed in which these three po- 
tential mediators were added to the first ABE model to eval- 
uate the methods by which the TM was effective in increas- 
ing agreement to follow-up. The multivariate model to pre- 
dict abstinence at follow-up included the variables used for 
building the first “agree to follow-up” model with two addi- 
tional variables: cessation medications ordered at discharge, 
and cessation medications reported being taken at follow- 
up. As in the analysis of agreement to follow-up, the three 
mediating covariates were added into a second multivariate 
model to evaluate the methods by which the TM was effec- 
tive in increasing patient-reported abstinence at follow-up. 
RESULTS 
Patient Flow 
Among patients discharged between January 25 and April 
25, 2013, there were 323 unique orders/referrals for tobacco 
cessation consults. Of these, 232 patients were seen and re- 
ceived the SM. Of these, 40 did not have access to a phone 
for follow-up. Of the remaining 192 patients eligible for 
follow-up, 162 (84.4%) agreed to follow-up. Of these, 131 
were reached, and 51 (38.9%) self-reported continuous ab- 
stinence since discharge (26.6% of those eligible for follow- 
up) ( Figure 1 ). 
Among patients discharged between April 29 and 
November 30, 2013, there were 374 unique orders/referrals 
for tobacco cessation consults. Of these, 298 were seen and 
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Eligible for 
follow-up call
n = 192
Eligible for 
follow-up call
n = 236
Standard Cessation 
Message (SM)
Jan 25-April 25
Tailored Cessation 
Message (TM)
April 29 – Nov 30
In hospital 
consults 
completed
n = 298 
(79.7%)
In hospital 
consults 
completed
n = 232 
(71.2%)
Agreed 
n =162 
(84.4%)
Agreed 
n = 232
(98.3%)
Patients reached for follow-up
N = 131 (80.9%)
Patients reached for follow-up
N = 177 (76.3%)
Abstinent
n = 51
(38.9%)
Reduced
< previous use
n = 56
(42.7%)
Reduced
< previous use
n = 63
(35.6%)
Abstinent
n = 94
(53.1%)
Relapsed > 
previous use
n= 24
(18.3%)
Relapsed > 
previous use
n = 20
(11.3%)
Incomplete n=76 (20.2%)
•Discharged early n = 35
•Cancelled orders n = 3
•Clinically unable to see n=11
• Patient refused n=10
•Unavailable 3+ attempts=0
•Other n=17 (death=1, other=3, 
not willing=13)
Incomplete n=91 (28.2%)
•Discharged early n = 34
•Cancelled orders n = 4
•Clinically unable to see n=11
• Patient refused n=4
•Unavailable 3+ attempts = 4
•Other n=34 (interrupted=3, 
other=2, not willing=29)
Excluded n=40 (17.2%)
Not eligible for follow-up (no 
phone in prison, nursing 
home, rehab) 
Excluded n=62 (20.8%)
Not eligible for follow-up
(no phone in prison, nursing 
home, rehab, 1 missed) 
Not reached n=31 (19.1%)
•Not reached after 3+ attempts 
n=20
•Not at given number n=6
• In treatment facility n=3
•Death n=1
•Other n=1
Not reached n=55 (23.7%)
•Not reached after 3+ attempts 
n=36
•Not at given number n=16
• In treatment facility n=3
•Death n=0
•Other n=0
Declined
n=30
(15.6%)
Declined 
n=4
(1.7%)
Figure 1: Shown here is the patient flow for the study. SM, standard message; TM, tailored message; consult, tobacco 
cessation consultation 
received the TM. Of these, 61 did not have access to a 
phone for follow-up. and 1 patient was missed. Of the re- 
maining 236 eligible for follow-up, 232 (98.3 %) agreed 
to follow-up. Of these, 177 were reached, and 94 (53.1%) 
reported continuous abstinence since discharge (39.8% of 
those eligible for follow-up) ( Figure 1 ). 
Demographic and Smoking History Comparisons 
Few statistically significant differences in demographics 
were exhibited between the treatment groups when all pa- 
tients who completed consults were compared. The TM 
group had a significantly higher proportion of patients with 
in-hospital cessation medication orders (74.8% vs. 64.7%, 
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Table 2. Multivariate Regression Results ∗ Predicting Patient Agreement to a Postdischarge Follow-Up Call: Com- 
parisons for Tailored Message (TM) Group [ n = 233] † vs. Standard Message (SM) Group [ n = 176] † 
Covariates Multivariate Model 1 ‡ Multivariate Model 2 §
Estimate of OR (95% 
Confidence Intervals) p Value 
Estimate of OR (95% 
Confidence Intervals) p Value 
Variables from 
RDW and consult 
questionnaire 
Group (TM vs. SM) 10.83 (3.66–32.04) < 0.0001 5.75 (1.83–18.03) 0.0027 
Medicare (Y vs. N) 2.75 (0.90–8.36) 0.0750 2.60 (0.82–8.29) 0.1056 
Cravings in the hospital? (Y vs. N) 2.65 (1.18–5.98) 0.0118 2.52 (1.04–6.09) 0.0405 
Other hospital staff discuss? (Y vs. N) 2.43 (1.02–5.81) 0.0451 2.14 (0.85–5.36) 0.1065 
Consult mediators Willingness score = 10 (Y vs. N) N/A 5.37 (1.65–17.50) 0.0052 
Confidence score = 10 (Y vs. N) N/A 0.42 (0.11–1.64) 0.2117 
Consult time 10 min. or more (Y vs. N) N/A 3.88 (1.44–10.50) 0.0075 
∗ Using augmented backward elimination (ABE) technique as described in Statistical Methods. 
† Sample size reflects 19 subjects excluded due to missing values for one or more covariates. 
‡ Covariates evaluated included Research Data Warehouse (RDW)–sourced and consult assessment responses, no consult mediators. 
§ Covariates included previous model with additional consult mediators. 
OR, odds ratio; willingness score, willingness to remain abstinent from smoking postdischarge; confidence score, confidence in remaining 
abstinent from smoking postdischarge. 
p = 0.0109), and marginally higher proportions on Medi- 
care (31.9% vs. 24.1%, p = 0.0501) and having a cardiovas- 
cular diagnosis (26.2% vs. 19.8%, p = 0.0868), compared 
to SM group patients. ( Table 1a ) 
Differences between the groups in smoking history vari- 
ables were that higher proportions of TM patients reported 
cravings in the hospital (58.8% vs. 44.1%, p = 0.0008) 
and having their first cigarette less than 30 minutes af- 
ter waking (85.9% vs. 70.3%, p < 0.0001) compared to 
SM patients. Higher proportions of SM patients smoked 
while hospitalized (13.1% vs. 5.4%, p = 0.0018), had cut 
down recently (29.8% vs. 22.2%, p = 0.0452), lived with 
other smokers (53.7% vs. 45.3%, p = 0.0559), and had 
other hospital staff discuss tobacco use during hospitaliza- 
tion (40.0% vs. 24.8%, p = 0.0002). Additional group dif- 
ferences were seen in proportions of patients who reported 
high levels of confidence in quitting (SM 18.1% vs. TM 
11.1%, p = 0.0213) and those whose consults lasted greater 
than 10 minutes (TM 69.1% vs. SM 35.8%, p < 0.0001). 
( Table 1b ) 
Predictors of Agreement to Follow-Up 
In the univariate analysis, TM patients were signifi- 
cantly more likely than SM patients to agree to follow- 
up (odds ratio [OR] = 10.17, 95% confidence interval 
[CI] = 3.71–31.07, p < 0.0001). Bivariate analyses yielded 
nine covariates with p values less than 0.2500 to in- 
clude into initial multivariate ABE models (correlated in- 
surance/Medicaid/Medicare variables were evaluated sepa- 
rately). Five of these covariates were eliminated according to 
ABE criteria, and the final multivariate model included the 
message group variable along with three remaining signifi- 
cant covariates: Medicare coverage, cravings in the hospital, 
and anyone else in the hospital discussed tobacco use ( Table 
2 ). After adjusting for these confounders, the TM group re- 
mained significantly more likely than the SM group to agree 
to follow-up (OR = 10.83, p < 0.0001). Patients covered 
by Medicare, those experiencing cravings in the hospital, 
and those who had other hospital staff discuss tobacco use 
with them were all more than twice as likely as their coun- 
terparts to agree to follow-up ( p values 0.0750, 0.0118, and 
0.0451, respectively). 
Three potentially mediating consult variables (consult 
time, willingness score, and confidence score) were added to 
the model to evaluate the methods by which the TM was ef- 
fective in increasing agreement to follow-up ( Table 2 ). The 
OR for TM vs. SM groups in this model decreased substan- 
tially (OR = 5.75, p = 0.0027), with the variables for will- 
ingness score and consult time contributing significantly to 
the final model ( p values 0.0052 and 0.0075, respectively). 
These findings suggest that the TM may have contributed 
to increasing agreement to follow-up in part by increasing 
subjects’ willingness to try to remain abstinent during their 
recovery in order to reduce the risk of poorer recovery out- 
comes and to engage in longer consult times (10 minutes 
or more) than the SM. ORs and their CIs are presented in 
Table 2 . 
Predictors of Abstinence at Follow-Up 
Univariate analysis showed TM patients were also signifi- 
cantly more likely than SM patients to self-report contin- 
uous abstinence since discharge at follow-up (OR = 1.78, 
95% CI = 1.12–2.81, p = 0.0141). Bivariate analyses 
yielded 14 covariates with p values less than 0.2500 to 
include into initial multivariate ABE models (correlated in- 
surance/Medicaid/Medicare variables were evaluated sep- 
arately). Five of these covariates were eliminated accord- 
ing to ABE criteria, and the final multivariate model 
included the message group variable and covariates age, 
Medicare, cardiovascular (CV) diagnosis, length of hospi- 
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Table 3. Multivariate Regression Results ∗ Predicting Patient-Reported Abstinence from Smoking at Postdischarge 
Follow-Up Call: Tailored Message (TM) [ n = 175] † vs. Standard Message (SM) [ n = 123] † 
Multivariate Model 1 ‡ Multivariate Model 2 §
Covariates 
Estimate of OR (95% 
Confidence Intervals) p Value 
Estimate of OR (95% 
Confidence Intervals) p Value 
Variables from 
RDW and consult 
questionnaire 
Group (TM vs. SM) 2.07 (1.17–3.66) 0.0130 2.02 (1.09–3.72) 0.0245 
Average age (at admission) 1.05 (1.03–1.08) < 0.0001 1.05 (1.02–1.07) 0.0002 
Medicare (Y vs. N) 0.39 (0.19–0.78) 0.0080 0.42 (0.20–0.86) 0.0173 
Primary discharge diagnosis: CV (Y vs. N) 2.07 (1.11–3.85) 0.0223 1.92 (1.02–3.60) 0.0434 
Length of stay (per day increase) 1.10 (1.04–1.16) 0.0008 1.09 (1.03–1.16) 0.0019 
Cravings in the hospital? (Y vs. N) 0.38 (0.21–0.69) 0.0013 0.41 (0.23–0.75) 0.0038 
Still smoking in hospital (Y vs. N) 0.14 (0.02–0.87) 0.0349 0.12 (0.02–0.75) 0.0234 
Cut down recently? (Y vs. N) 1.85 (0.97–3.52) 0.0602 1.67 (0.86–3.25) 0.1297 
Smoking allowed inside? (Y vs. N) 0.49 (0.26–0.91) 0.0241 0.51 (0.27–0.95) 0.0351 
Meds at follow-up (Y vs. N) 4.46 (2.37–8.39) < 0.0001 4.76 (2.50–9.06) < 0.0001 
Consult mediators Willingness score = 10 (Y vs. N) N/A 1.52 (0.82–2.83) 0.1878 
Confidence score = 10 (Y vs. N) N/A 2.10 (0.88–5.01) 0.0948 
Consult time 10 min. or more (Y vs. N) N/A 1.33 (0.71–2.48) 0.3709 
∗ Using augmented backward elimination (ABE) technique as described in Statistical Methods. 
† Sample size reflects 10 subjects excluded due to missing values for one or more covariates. 
‡ Covariates evaluated included Research Data Warehouse (RDW)–sourced and consult assessment responses, no consult mediators. 
§ Covariates included previous model with additional consult mediator. 
OR, odds ratio; CV, cardiovascular; willingness score, willingness to remain abstinent from smoking postdischarge; confidence score, 
confidence in remaining abstinent from smoking postdischarge. 
tal stay, cravings in the hospital, still smoking in the hospi- 
tal, recently cut down, smoking allowed inside the home, 
and cessation meds being taken at follow-up ( Table 3 ). Af- 
ter adjusting for these confounders, the TM group con- 
tinued to be significantly more likely than the SM group 
to remain abstinent (OR = 2.07, 95% CI = 1.17–3.66, 
p = 0.0130). Abstinence increased with increasing age and 
longer hospital stay ( p values < 0.0001 and 0.0008, re- 
spectively). Patients who had reported cutting down to- 
bacco use at admission were more likely than their coun- 
terparts to self-report continuous abstinence until follow- 
up (OR = 1.85, p = 0.0602), as were patients with a CV 
diagnosis (OR = 2.07, p = 0.0223). Those taking cessation 
medications at follow-up were significantly more likely to 
be abstinent (OR = 4.46, p < 0.0001). Medicare patients, 
those experiencing cravings in the hospital, and those who 
allowed smoking inside their homes were all less than half 
as likely to remain abstinent at follow-up ( p values 0.0080, 
0.0013, and 0.0241, respectively), and those who smoked 
during their hospital stay were significantly less likely to be 
abstinent at follow-up (OR = 0.14, p = 0.0349). 
The addition of consult-specific mediators into the 
ABE–derived model yielded minimal change for TM 
vs. SM groups (OR = 2.02, 95% CI = 1.09–3.72, 
p = 0.0245) ( Table 3 ). This suggests that although the 
TM group was significantly associated with increased absti- 
nence at follow-up, the method by which this association 
arose was other than increased willingness or confidence 
in abstaining after discharge, or increased time spent in 
consult ( Table 3 ). 
DISCUSSION 
This evaluation compares two messages designed to engage 
patients in a tobacco cessation intervention in a real-world 
hospital setting. After our Consult Service protocol was im- 
plemented in 2007, an ongoing QI process was undertaken 
to increase treatment effectiveness. As part of our review, we 
learned that medical staff seldom educated patients about 
how smoking could directly affect their recovery, a poten- 
tially important factor for increasing willingness to partici- 
pate in cessation treatment and to remain abstinent during 
recovery. This finding led to a QI project to test whether 
including tailored information about smoking risks for pa- 
tients’ recovery vs. a more general health benefits message 
could help improve engagement in tobacco cessation while 
hospitalized and agreement for the critical postdischarge 
follow-up step. Our primary interest was increasing patient 
interest while hospitalized, but we also assessed self-reported 
continuous abstinence for those completing follow-up two 
to three weeks after discharge. When looking for a com- 
mon denominator to use in our TM, we found that educa- 
tion about the immediate risks of carbon monoxide (CO) 
on healing and recovery 3,5–7 , 28–30 could be relevant to most 
hospital patients. We added the tailored CO risk message 
for the TM group, but kept the overall intervention the 
same for both groups. We found that the TM group was 
more likely to agree to follow-up ( p < 0.0001) compared 
to the SM group. We found that patients receiving the 
TM were more likely to report maximum scores ( = 10) on 
“willingness to remain abstinent” and to engage in longer 
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consult times ( > 10 minutes), suggesting that linking the 
increased risks of continued smoking to hospital recovery 
improved patient interest in tobacco cessation and agree- 
ment for follow-up. When contacted at follow-up, the TM 
group self-reported a higher rate of continuous abstinence 
compared to the SM group ( p = 0.0130). However, the 
variables that helped explain effectiveness of the TM for in- 
creasing “agree to follow-up” were not significant predictors 
of abstinence at follow-up. 
Overall, these data suggest that when patients are pre- 
sented with a smoking risk message specific to their imme- 
diate hospital recovery, they may become more interested 
and act on that information. These results support Gilbert 
and colleagues’ findings that a tailored risk letter engaged 
more smokers to participate in smoking cessation than a 
general risk letter. 36 In addition, a recent systematic review 
found that new information about chemicals contained in 
tobacco smoke can lead to behavior change, 37 supporting 
our use of messaging regarding CO exposure risks. 38 These 
data also support anecdotal comments from TTS staff that 
some TM patients reported that their willingness to agree to 
follow-up and to remain abstinent was due, in part, to new 
information about their risk of poor recovery outcomes. 
These findings suggest that additional clinician education 
on how to deliver this type of risk message to patients who 
smoke would be helpful. 
Our data on abstinence at follow-up are less clear. We 
hypothesized that increased interest in cessation and agree- 
ment for follow-up during hospitalization could lead to 
higher abstinence rates after discharge. Although our data 
showed this to be the case, the mechanisms by which in- 
creased participation in our cessation intervention resulted 
in increased abstinence after discharge are not evident. The 
reasons smokers give for why they are willing to attempt ab- 
stinence are often unique, so it may be helpful in the future 
when collecting follow-up data to inquire more specifically 
about their reasons for maintaining abstinence. 
Tobacco dependence is a chronic disease characterized 
by periods of abstinence (remission) and relapse. 2 Long- 
term abstinence is a gold standard outcome, but many hos- 
pital patients will relapse and return to smoking within 
months. 19 Because tobacco smoke, and particularly CO, 
has such immediate and negative effects postdischarge on 
immune response, 3 wound healing, 29 , 30 bone unions, 4 and 
cardiac effort, 5–7 , 28 any period of even a few weeks of ab- 
stinence following hospital discharge can improve recovery 
outcomes. 39 A recent study reported that less than half of 
patients who smoke may be willing to engage in smoking 
cessation in the hospital and suggested that new ways to 
engage more patients in treatment are needed. 40 An en- 
gagement message linking tobacco abstinence to hospital 
recovery appears to be a message that resonates with pa- 
tients, can interest more patients in hospital smoking cessa- 
tion treatment, and could easily be reinforced in discharge 
and follow-up instructions. 
Strengths and Limitations 
This analysis involved nearly 700 hospital patients, and the 
design allowed delivery of either the SM or TM to a distinct 
group of patients based on month of admission. Messaging 
that educates patients about the risks of tobacco use and 
CO exposure on their immediate recovery is one that hos- 
pitals can readily incorporate into usual hospital workflow. 
Even patients in hospitals without specialized cessation ser- 
vices might benefit from having clinicians provide such a 
risk message coupled with referral to a quitline for follow- 
up. 
Our hospital is a regional academic medical center and 
Level 1 trauma center with a patient population that may 
be different from other hospitals. This analysis did not ad- 
dress the effects of the two approaches by race or ethnic- 
ity. EHR data were incomplete regarding race/ethnicity and 
not included in the analysis. Although hospital medical staff
did not generally provide patients with detailed informa- 
tion about the effects of smoking on their illness/condition 
and recovery, some specialists (for example, cardiology, pul- 
monary) may have provided more specific information than 
others. At the other extreme, anecdotal reports from the 
TTSs indicate that some patients were unaware that a con- 
sultation had been ordered. We assumed that these variabili- 
ties existed independently of the messages from our Consult 
Service, thereby affecting both groups equally. 
Patients seen by our TTS staff received varying amounts 
of information, within our protocol limitations, based on 
their interest and ability to participate in the consult. Our 
staff were trained to follow the protocol, particularly for the 
engagement message, but they were also trained to respond 
to patients’ interests, needs, and questions. Longer consult 
times had an effect on the outcome, as they were predictive 
of increased agreement for follow-up. Although some of the 
longer consult times likely contained more complete health 
risk explanations because some patients were more curious, 
our anecdotal information suggests that these longer con- 
sults also included conversations about other topics (such 
as the perceived quality of their hospital care). 
Like some other clinically based programs, we did 
not biochemically verify patient self-reported abstinence 
rates, 20 , 23 , 25 which could have resulted in an overestima- 
tion of abstinence rates. Finally, the hospital did not assess 
expired breath CO at admission or during hospitalization. 
It may be that assessing CO levels and providing those data 
to patients would enhance the effects of CO risk messaging. 
CONCLUSION 
Continued smoking following discharge is a risk to pa- 
tient safety. However, patients who smoke often have little 
interest in smoking cessation while hospitalized. Our QI 
project was aimed at increasing patient interest and partic- 
ipation in smoking cessation treatment and follow-up. We 
Volume 46, No. 5, May 2020 259 
found that providing a smoking cessation engagement mes- 
sage linking risks of continued smoking, including carbon 
monoxide exposure, to hospital patients’ immediate post- 
discharge recovery resulted in higher rates of agreement to 
follow-up and willingness to remain abstinent, and longer 
consult times, compared to our standard health benefit mes- 
sage without links to immediate recovery. While the pri- 
mary message effect was increased patient interest in our 
cessation treatment protocol and follow-up, patients receiv- 
ing the tailored-risk message were also more likely to self- 
report continuous abstinence at follow-up. The TM was 
subsequently integrated into our tobacco dependence in- 
tervention as standard of care. This was a low staff burden 
modification to our existing protocol. Other hospitals and 
health care settings may benefit from providing similar risk 
messaging in their tobacco dependence interventions. 
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